BCG Vaccine Description
Bacille Calmette-Guerin (BCG) vaccine is an attenuated, live culture preparation of the Bacillus of Calmette and Guerin (BCG) strain of Mycobacterium bovis. The TICE® strain used in this BCG vaccine preparation was developed at the University of Illinois from a strain originated at the Pasteur Institute.
The BCG is a vaccine against tuberculosis, with protective non-specific effects against other respiratory tract infections and in vivo studies, and reported morbidity and mortality reductions as high as 70%.
The NIH says the BCG vaccine is a fairly safe vaccine and it is not associated with severe complications.
Many foreign-born persons have been BCG-vaccinated. As an example, India, with the world's highest TB burden, introduced BCG in mass immunization beginning in 1948.
TB is the leading cause of death from infectious disease worldwide, causing about 1.3 million deaths per year, mostly in the developing world. The respiratory virus M tuberculosis is spread via airborne transmission and more often affects men, who account for 60% of all cases, according to a recent study published by the CDC in May 2020.
Newborns and infants have the greatest benefit from BCG vaccination. Routine neonatal vaccination is recommended by the WHO in countries with moderate to severe prevalence of tuberculosis.
The reduction in childhood mortality may be due to epigenetic reprogramming of the nucleotide-binding oligomerization domain (NOD2) receptor.
This is because of suggestions the BCG vaccine has other beneficial effects on the immune system that could protect against other infections. A 2019 observational study reported the vaccine is related to fewer deaths from certain infections other than from TB in low-income countries.
And recently, a non-peer-reviewed study published on June 12, 2020, found that mandatory BCG was associated with a significantly slower climb in both confirmed cases and deaths during the first 30-day period of an outbreak.
In the absence of evidence, the WHO does not recommend BCG vaccination for the prevention of COVID-19 disease. The WHO continues to recommend neonatal BCG vaccination in countries or settings with a high incidence of tuberculosis.
Furthermore, the BCG vaccine is not generally recommended for use in the USA because of the low risk of infection with Mycobacterium tuberculosis.
However, there are active phase 3 and 4 clinical trials in the USA, Australia, and the Netherlands evaluating the potential protective benefits from BCG vaccination related to COVID-19 disease prevention.
BCG Vaccine Indication
BCG is used in many countries to prevent childhood tuberculous, meningitis, and other diseases. The BCG vaccine also helps fight other viruses, such as respiratory infections. TB is a serious infection that affects the lungs and sometimes other parts of the body, such as the bones, joints, and kidneys.
For example, one study conducted in West Africa found that children who were vaccinated with BCG had about a 50% reduction in overall mortality, largely because the vaccine reduced respiratory infections and sepsis, or blood poisoning.
A study published on May 2, 2019, reported the effect of BCG on an experimental viral infection in humans has been demonstrated. These effects are thought to be mediated via the induction of innate immune memory and heterologous lymphocyte activation, resulting in enhanced cytokine production, macrophage activity, T-cell responses, and antibody titers.
On April 6, 2020, researchers on the Johns Hopkins Bloomberg College of Public Well being discovered that the COVID-19 mortality fee amongst countries that use the Bacillus Calmette-Guérin (BCG) vaccination was eight instances lower than in these that don’t.
In the USA, BCG vaccination should be considered for very select persons who meet specific criteria and in consultation with a TB expert, says the CDC.
And, BCG vaccination should not be given to persons who are immunosuppressed (e.g., persons who are HIV infected) or who are likely to become immunocompromised (e.g., persons who are candidates for organ transplant).
BCG vaccination should only be considered for children who have a negative tuberculin skin test and who are continually exposed, and cannot be separated from, adults who are untreated or ineffectively treated for TB disease or have TB caused by strains resistant to isoniazid and rifampin.
Furthermore, BCG vaccination should not be given during pregnancy. Even though no harmful effects of BCG vaccination on the fetus have been observed, further studies are needed to prove its safety.
BCG vaccination may also be recommended for older children who have an increased risk of developing TB, such as children who have recently arrived from countries with high levels of TB, including those in Africa, the Indian subcontinent, parts of southeast Asia, parts of South and Central America, and parts of the Middle East, and children who have come into close contact with somebody infected with respiratory TB, says the CDC.
A single dose of M. bovis bacillus Calmette-Guérin immunotherapy has a great therapeutic benefit in the treatment of a non-invasive form of bladder cancer. It is administered intravesically and proven benefits include the delay and prevent progression of the malignancy
BCG Vaccine Dosage
Approved dose: BCG vaccine can be given either intracutaneously or intradermally. Research is currently being conducted on respiratory administration since natural infection, and sensitization to Mycobacterium tuberculosis in humans tend to occur in the respiratory system.
BCG Vaccine News
- July 9, 2020 - Researchers at the National Institute of Allergy and Infectious Diseases of the U.S. NIH identified a linkage between the very old Bacille Calmette-Guerin (BCG) and the COVID-19 disease after comparing mortality rates around the world.
- July 3, 2020 - Researchers at the University of Sydney and Centenary Institute are repurposing an existing tuberculosis vaccine Bacille Calmette-Guérin (BCG) with major components of the SARS-CoV-2 virus, creating a new vaccine candidate called BCG:CoVac. In BCG:CoVac, the BCG vaccine is used as a vehicle to deliver distinctive proteins that originate from the SARS-CoV-2 virus surface. The goal is for the human immune system to develop a memory of SARS-CoV-2 and develop immunity.
- June 12, 2020 - A non-peer-reviewed study found that mandatory BCG was associated with a significantly slower climb in both confirmed cases and deaths during the first 30-day period of an outbreak. This analysis suggests that mandated BCG vaccination can be effective in the fight against COVID-19.
- June 11, 2020 - The Washington Post wrote 'Can old vaccines from science's medicine cabinet ward off coronavirus? ... Prominent researchers hope to test the vaccine against the coronavirus.'
- May 28, 2020 - Bulgarian scientists suggest that the Balkan country's high rate of BCG vaccination—as well as an early lockdown—helped it to escape the worst of the pandemic. "BCG generates a powerful immune stimulation.
- May 27, 2020 - A Phase III, two-group multicentre, randomized controlled trial in up to 10,078 healthcare workers to determine if BCG vaccination reduces the incidence and severity of COVID-19 disease.
- May 26, 2020 - The NIH published a Bacillus Calmette Guerin (BCG) summary by Chika N. Okafor; Ayesan Rewane; Ifeanyi I. Momodu.
- May 20, 2020 - Researchers at Baylor College of Medicine and four other institutions around the country are working to find out if it also can work against COVID-19. They are now recruiting for a clinical trial to test the vaccine. “Epidemiological studies show that if you’re BCG vaccinated, you have a decreased rate of other infections,” said Dr. Andrew DiNardo, assistant professor of medicine – infectious diseases at Baylor.
- May 13, 2020 - A study published in JAMA does not support the idea that BCG vaccination in childhood has a protective effect against COVID-19 disease later in adulthood.n this cohort of Israeli adults aged 35 to 41 years, BCG vaccination in childhood was associated with a similar rate of positive test results for SARS-CoV-2 compared with no vaccination.
- May 7, 2020 - Texas A&M University researchers vaccinated more than 50 health care workers on Wednesday as they started a clinical trial for a vaccine they believe can mitigate the effects of COVID-19. The BCG vaccinations administered at the Bryan Medical Center were the first ones in the U.S. clinical trial. BCG won’t prevent people from contracting COVID-19, but researchers believe it may allow a person’s immune response to kill nearly any type of infection, meaning it essentially broadly strengthens people’s immune response.
- May 4, 2020 - Researchers at Baylor College of Medicine and 4 other institutions around the country are working to find out if the BCG vaccine can work against COVID-19. They are now recruiting for a clinical trial to test the vaccine.
- April 30, 2020 - An article published in The Lancet says 'If the BCG vaccine or another inducer of trained immunity provides non-specific protection to bridge the gap before a disease-specific vaccine is developed, this would be an important tool in the response to COVID-19 and future pandemics.'
- April 29, 2020 - This Phase 3 study evaluates the efficacy of BCG to improve the clinical course of Covid-19 infection and to prevent absenteeism in order to safeguard continuous patient care.
- April 28, 2020 - Dr. Jeffrey Cirillo at the Texas A&M Health Science Center is leading a group of world-renown institutions in a vaccine clinical trial that could prevent COVID-19 disease cases in just 6-months. This phase 4 vaccine study will include 1,800 participants and researchers from Harvard’s School of Public Health, the University of Texas MD Anderson Cancer Center in Houston, Cedars Sinai Medical Center in Los Angeles, and the Baylor College of Medicine in Houston.
- April 8, 2020: A non-peer-reviewed study found a significant difference in the CFR between the two groups of countries. Our data further support the view that universal BCG vaccination has a protective effect on the course of COVID-19 probably preventing progression to severe disease and death.
- April 7, 2020: A phase 3 study is an Open-label, two-group, randomized controlled trial in up to 4,170 healthcare workers to determine if BCG vaccination reduces the incidence and severity of COVID-19 disease during the 2020 pandemic.
- April 6, 2020 - Researchers on the Johns Hopkins Bloomberg College of Public Well being discovered that the COVID-19 mortality fee amongst countries that use the Bacillus Calmette-Guérin (BCG) vaccination was eight instances lower than in these that don’t.
- March 2020: Countries with a national program of whole population BCG vaccination appear to have a lower incidence and death rate from COVID-19. This may be due to the known immunological benefits of BCG vaccination.
- March 12, 2020: Our results show that BCG and BCGΔBCG1419c protect T2D mice against TB via different participation of T and B lymphocytes, dendritic cells, and pro-inflammatory cytokines.
- December 2019 - An observational study reported the vaccine is related to fewer deaths from certain infections other than from TB in low-income countries.
- September 25, 2019: This retrospective review was a 60-year follow-up of a clinical trial of the BCG vaccine that included 2963 participants vaccinated at a median age of 8 years.
- May 2, 2019 - The discovery of innate immune memory has greatly improved our understanding of the mechanisms underlying the non-specific effects induced by BCG vaccination. However, a full understanding of the molecular mechanisms that underlie this phenomenon is still evolving.
- December 29, 2018: In T1D, BCG vaccination restored blood sugars to near normal, even in patients with advanced disease of >20 years duration. This clinically important effect may be driven by the resetting of the immune system and the shifting of glucose metabolism from overactive oxidative phosphorylation, a state of minimal sugar utilization, to aerobic glycolysis, a state of high glucose utilization, for energy production.
- May 30, 2017: Studies in mice have shown a beneficial effect of the BCG vaccine against allergic asthma, multiple sclerosis, and diabetes. However, the understanding of its mechanism is still fragmentary and requires further in-depth research. Some observational or intervention studies in humans have also suggested a beneficial effect, but definitive evidence for this requires confirmation in carefully conducted prospective studies.
- September 1995: This CDC report updates and replaces previous recommendations regarding the use of Bacillus of Calmette and Guerin (BCG) vaccine for controlling tuberculosis (TB) in the United States (MMWR 1988;37:663-4, 669-75).
- 1995 - Generation of nitric oxide and clearance of interferon-gamma after BCG infection are impaired in mice that lack the interferon-gamma receptor.
BCG Vaccine Clinical Trials
BCG is currently involved in 102 active and recruiting clinical trials covering various conditions. Click here to review the various ongoing clinical trials. Active BCG Clinical Trials Focused on Preventing SARS-CoV-2 Infections From Developing COVID-19 Disease include the following:
- Clinical Trial NCT04327206: BCG Vaccination to Protect Healthcare Workers Against COVID-19 (BRACE) - last update on May 27, 2020.
- Clinical Trial NCT04328441: Reducing Health Care Workers Absenteeism in Covid-19 Pandemic Through BCG Vaccine (BCG-CORONA) - last update on April 29, 2020.
- Clinical Trial NCT04348370: BCG Vaccine for Health Care Workers as Defense Against COVID 19 (BADAS) - last update on May 27, 2020.